Ask AI

Team Strategies for Overcoming Challenges to Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer

Enhance your ability to optimally integrate CDK4/6 inhibitors into practice for HR-positive/HER2-negative early breast cancer based on key clinical evidence and expert recommendations through a certified on-demand webcast and interactive case challenges as well as a ClinicalThought commentary and downloadable slides.

Share

Program Content

Events

Activities

Early Breast Cancer Local Live
Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer 
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 27, 2026

Activities

Early Breast Cancer Management Forum
ClinicalThought Expert Office Hours Forum: Navigating Treatment Decisions in High-Risk HR+/HER2- Early Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 20, 2026

Activities

CDK4/6 Inhibitors HR Positive HER2 Negative EBC
Case Challenge: Optimizing Patient–Provider Communication About CDK4/6 Inhibitors for Treatment of HR+/HER2- EBC
Case Challenge
Congratulations: You achieved a completion on 04/09/2022

Released: May 22, 2026

Expires: November 21, 2026

Faculty

cover img faculity

Jame Abraham, MD, FACP

Enterprise Chairman, Department of Hematology and Medical Oncology
Professor of Medicine
Lerner College of Medicine
Cancer Institute, Cleveland Clinic
Cleveland, Ohio

cover img faculity

Erin F. Cobain, MD

Associate Professor of Internal Medicine
Director, Precision Oncology Program
Breast Cancer Clinical Research Team Co-Chair
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

cover img faculity

Laura A. Huppert, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

cover img faculity

Komal Jhaveri, MD, FACP, FASCO

Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

cover img faculity

Irene M. Kang, MD

Medical Director of Women’s Health Oncology
Assistant Professor of Medical Oncology and Therapeutics Research
City of Hope, Orange County
Irvine, California

cover img faculity

Ashley Martinez, DNP, APRN, FNP-BC, AOCNP, CPHQ, NEA-BC, NPD-BC

Director, Advanced Practice
UT MD Anderson Cancer Center
Houston, Texas

cover img faculity

Payal D. Shah, MD

Assistant Professor
Division of Hematology-Oncology
Basser Center for BRCA
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by educational grants from Lilly and Novartis.

Lilly

Novartis

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner